Evidence map›Paper›PMID 38631854›Full record

ArticleInternal medicine (Tokyo, Japan)2024

Autopsy Case of Meningoencephalitis Induced by Nivolumab and Ipilimumab in a Patient Being Treated for Non-small Cell Lung Cancer.

Keisuke Shiraha, Hiromi Watanabe, Keiichi Fujiwara, Mayu Goda, Tomoyoshi Inoue, Miho Fujiwara, Suzuka Matsuoka, Yuki Takigawa, Sho Mitsumune, Kenichiro Kudo and 4 more

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Keisuke ShirahaDepartment of Respiratory Medicine, NHO Okayama Medical Center, Japan.
Hiromi WatanabeDepartment of Respiratory Medicine, NHO Okayama Medical Center, Japan.
Keiichi FujiwaraDepartment of Respiratory Medicine, NHO Okayama Medical Center, Japan.
Mayu GodaDepartment of Respiratory Medicine, NHO Okayama Medical Center, Japan.
Tomoyoshi InoueDepartment of Respiratory Medicine, NHO Okayama Medical Center, Japan.
Miho FujiwaraDepartment of Respiratory Medicine, NHO Okayama Medical Center, Japan.
Suzuka MatsuokaDepartment of Respiratory Medicine, NHO Okayama Medical Center, Japan.
Yuki TakigawaDepartment of Respiratory Medicine, NHO Okayama Medical Center, Japan.
Sho MitsumuneDepartment of Respiratory Medicine, NHO Okayama Medical Center, Japan.
Kenichiro KudoDepartment of Respiratory Medicine, NHO Okayama Medical Center, Japan.
Akiko SatoDepartment of Respiratory Medicine, NHO Okayama Medical Center, Japan.
Ken SatoDepartment of Respiratory Medicine, NHO Okayama Medical Center, Japan.
Yoko ShinnoDepartment of Pathology, NHO Okayama Medical Center, Japan.
Takuo ShibayamaDepartment of Respiratory Medicine, NHO Okayama Medical Center, Japan.
Okayama Medical Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 75-year-old woman with stage IVB (cT2bN3M1b) lung adenocarcinoma was administered nivolumab, ipilimumab, carboplatin, and paclitaxel. Fourteen days after receiving chemotherapy, she experienced an impaired consciousness and a cerebrospinal fluid analysis revealed high protein levels and pleocytosis. She was diagnosed with nivolumab- and ipilimumab-induced encephalitis and was treated with corticosteroids which were tapered to 10 mg/day, with no symptom recurrence. She died 18 weeks after the initial presentation, as the cancer worsened. An autopsy showed encephalitis and CD8

Indexed as

AutopsyCarcinoma, Non-Small-Cell LungIpilimumabLung NeoplasmsMeningoencephalitisNivolumabAgedAntineoplastic Combined Chemotherapy ProtocolsFatal OutcomeFemaleHumansIpilimumabNivolumabautopsyimmune checkpoint inhibitoripilimumabmeningoencephalitisnivolumab

Identifiers

PMID38631854
PMCPMC11729181
OpenAlexW4394803141

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.